[6][10] In March 2019, Deerfield announced a strategic partnership with Harvard University to fund the development of drugs and medical treatments.

[3][6] In April 2020, Deerfield acquired Melinta Therapeutics by exchanging $140 million in secured debt for 100% equity of the company after it filed for Chapter 11 bankruptcy protection.

[11][12] In May 2017, federal prosecutors filed insider trading charges against four individuals which were Christopher Worrall, a CMS employee, David Blaszczak, a political intelligence consultant and two of Deerfield's traders, Theodore Huber and Robert Olan.

Prosecutors said that using the information, bets were placed that the stocks of three radiation companies would fall earning Deerfield $1.85 in million profit in 2012.

In 2013, the Deerfield employees obtained further information from the contacts to short Fresenius Medical Care making $865,000 in profit.

[14][15][16][17] In August 2017, Deerfield agreed to pay $4.6 million to settle charges from the Securities and Exchange Commission that it failed to have adequate internal safeguards to prevent insider trading.